$-0.07
(Market cap
$1,699 Mln
Recently Viewed
Clear AllMarket cap
$1,699 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
7.6
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-3.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.3
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
366,916,896
CFO
$-280.44 Mln
EBITDA
$-470.96 Mln
Net Profit
$-433.84 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ATAI Life Sciences BV (ATAI)
| -0.9 | 21.0 | 4.8 | 187.6 | 28.5 | -- | -- |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
|---|---|---|---|
|
ATAI Life Sciences BV (ATAI)
| 207.5 | -47.0 | -65.1 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ATAI Life Sciences BV (ATAI)
|
4.1 | 1,698.8 | 4.1 | -660.1 | -2,789.5 | -390.4 | -- | 7.6 |
| 1.7 | 45.8 | 5.0 | -23.3 | -442.3 | -121 | -- | 3.6 | |
| 90.0 | 6,826.3 | 51.2 | -334.9 | -636.8 | -53.3 | -- | 8.8 | |
| 34.1 | 7,824.7 | 2,090.0 | 424.9 | 25.0 | 11.6 | 18.6 | 2.1 | |
| 19.5 | 1,127.4 | 16.1 | -199.0 | -975.8 | -207.1 | -- | 5.7 |
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation... of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. Read more
Founder & Chairman of the Supervisory Board
Mr. Christian Angermayer
Founder & Chairman of the Supervisory Board
Mr. Christian Angermayer
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ATAI Life Sciences BV (ATAI) is $4.06 (NASDAQ) as of 30-Apr-2026 13:37 EDT. ATAI Life Sciences BV (ATAI) has given a return of 28.52% in the last 3 years.
Since, TTM earnings of ATAI Life Sciences BV (ATAI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-1.43
|
1.83
|
|
2023
|
-5.57
|
0.92
|
|
2022
|
-2.72
|
1.59
|
|
2021
|
-6.27
|
2.79
|
The 52-week high and low of ATAI Life Sciences BV (ATAI) are Rs 6.75 and Rs 1.29 as of 30-Apr-2026.
ATAI Life Sciences BV (ATAI) has a market capitalisation of $ 1,699 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in ATAI Life Sciences BV (ATAI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.